Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

72.54
+0.87001.21%
Volume:639.39K
Turnover:45.58M
Market Cap:13.98B
PE:-17.34
High:72.67
Open:71.46
Low:70.35
Close:71.67
52wk High:75.10
52wk Low:25.34
Shares:192.71M
Float Shares:151.20M
Volume Ratio:0.50
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1844
EPS(LYR):-2.8793
ROE:-1789.67%
ROA:-43.47%
PB:-7.23
PE(LYR):-25.19

Loading ...

BridgeBio Pharma Chief Accounting Officer Maricel Apuli Reports Sale of Common Shares

Reuters
·
Yesterday

BridgeBio Pharma CEO Neil Kumar Reports Disposal of Common Shares

Reuters
·
Dec 09

BridgeBio Pharma on Track for Record High Close -- Data Talk

Dow Jones
·
Dec 03

BridgeBio Pharma Management to Join Fireside Chats at Major Healthcare Investor Conferences

Reuters
·
Nov 25

BridgeBio Pharma CEO Neil Kumar Reports Disposal of Common Shares

Reuters
·
Nov 25

Jefferies Remains a Buy on BridgeBio Pharma (BBIO)

TIPRANKS
·
Nov 24

Does Acoramidis' Survival Benefit in V142I Cardiomyopathy Shift the Bull Case for BridgeBio Pharma (BBIO)?

Simply Wall St.
·
Nov 22

BRIEF-BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 20

BridgeBio Pharma Grants Equity Awards to New Employees Under Amended 2019 Plan

Reuters
·
Nov 20

BridgeBio Pharma (BBIO) Receives a Buy from Jefferies

TIPRANKS
·
Nov 19

BridgeBio Pharma President and CFO Thomas Trimarchi Reports Disposal of Common Shares

Reuters
·
Nov 19

BridgeBio Pharma Soars 135% as FDA Milestones Spark Valuation Debate for 2025

Simply Wall St.
·
Nov 15

Director Hannah Valantine Reports Disposal of BridgeBio Pharma Inc. Common Shares

Reuters
·
Nov 15

BridgeBio Oncology Therapeutics Names Uneek Mehra as Chief Financial Officer

Reuters
·
Nov 13

BridgeBio Pharma CEO Neil Kumar Reports Disposal of Common Shares

Reuters
·
Nov 11

BridgeBio Pharma Publishes Study on Acoramidis for ATTR-CM

Reuters
·
Nov 10

BridgeBio presents data from ATTRibute-CM study on acoramidis

TIPRANKS
·
Nov 10

Biotech stocks are coming back. Here's what's driving the sector higher.

Dow Jones
·
Nov 09

BridgeBio Pharma Inc. publishes ATTRibute-CM trial results on transthyretin amyloid cardiomyopathy

Reuters
·
Nov 08

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

GlobeNewswire
·
Nov 08